Cancer Letters
Volume 238, Issue 2 , Pages 224-229 , 18 July 2006

Loss of imprinting and promoter usage of the IGF2 in laryngeal squamous cell carcinoma

  • Ivana Grbesa

      Affiliations

    • Laboratory of Molecular Pathology, Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka cesta 54, 10002 Zagreb, Croatia
    • ,
  • Mirko Ivkic

      Affiliations

    • Department of Otorhinolaryngology and Head and Neck Surgery, Sestre Milosrdnice University Hospital, 10000 Zagreb, Croatia
    • ,
  • Boris Pegan

      Affiliations

    • Department of Otorhinolaryngology and Head and Neck Surgery, Sestre Milosrdnice University Hospital, 10000 Zagreb, Croatia
    • ,
  • Koraljka Gall-Troselj

      Affiliations

    • Laboratory of Molecular Pathology, Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka cesta 54, 10002 Zagreb, Croatia
    • Corresponding Author InformationCorresponding author. Tel.: +385 1 456 0972; fax: +385 1 468 0119.

Received 9 May 2005 ,Revised 7 July 2005 ,Accepted 8 July 2005.

References 

  1. Yao X, Hu JF, Daniels M, Shiran H, Zhou X, Yan H, et al. A methylated oligonucleotide inhibits IGF2 expression and enhances survival in a model of hepatocellular carcinoma. J. Clin. Invest. 2003;111:265–273
  2. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al. Gene expression profiles in normal and cancer cells. Science. 1997;276:1268–1272
  3. Vu TH, Hoffman AR. Promoter-specific imprinting of the human insulin-like growth factor-II gene. Nature. 1994;371:714–717
  4. Ekström TJ, Cui H, Li X, Ohlsson R. Promoter-specific IGF2 imprinting status and its plasticity during human liver development. Development. 1995;121:309–316
  5. Sambrook J, Fritsch EF, Maniatis T. Extraction with phenol:chloroform. In:  Ford N,  Nolan C,  Ferguson M editor. Molecular Cloning: Laboratory Manual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1989;p. E.3–E.4
  6. Mitchell LG, Bodenteich A, Merril CR. Use of silver staining to detect nucleic acids. In:  Harwood AJ editors. Methods in Molecular Biology: Protocol for Gene Analysis. Totowa: Humana Press; 1994;p. 197–203
  7. Roy RN, Cecutti A, Gerulath AH, Steinberg WM, Bhavnani BR. Endometrial transcripts of human insulin-like growth factors arise by differential promoter usage. Mol. Cell. Endocrinol. 1997;135:11–19
  8. Cui H, Horon IL, Ohlsson R, Hamilton SR, Feinberg AP. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat. Med. 1998;4:1276–1280
  9. Cui H, Cruz-Correa M, Giardiello FM, Hutcheon DF, Kafonek DR, Brandenburg S, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science. 2003;299:1753–1755
  10. Vu TH, Chuyen NV, Li T, Hoffman AR. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor. Cancer Res. 2003;63:1900–1905
  11. Kim SJ, Park SE, Lee C, Lee SY, Jo JH, Kim JM, et al. Alternations in promoter usage and expression levels of insulin-like growth factor-II and H19 genes in cervical carcinoma exhibiting biallelic expression of IGF2. Biochim. Biophys. Acta. 2002;1586:307–315
  12. Mineo R, Fichera E, Liang SJ, Fujita-Yamaguchi Y. Promoter usage for insulin like growth factor II in cancerous and benign human breast, prostate, and bladder tissues and confirmation of a 10th exon. Biochem. Biophys. Res. Commun. 2000;268:886–892
  13. Pham NV, Nguyen MT, Hu JF, Vu TH, Hoffman AR. Dissociation of IGF2 and H19 imprinting in human brain. Brain Res. 1998;810:1–8
  14. Zhan S, Shapiro D, Zhan S, Zhang L, Hirschfeld S, Elassal J, et al. Concordant loss of imprinting of the human insulin-like growth factor II gene promoters in cancer. J. Biol. Chem. 1995;270:27983–27986
  15. Vu TH, Hoffman AR. Alternations in the promoter-specific imprinting of the human insulin like growth factor-II gene in Wilms' tumor. J. Biol. Chem. 1996;271:9014–9023
  16. Anderson J, Gordon A, McManus A, Shipley J, Pritchard-Jones K. Disruption of imprinted genes at chromosome region 11p15.5 in paediatric rhabdomyosarcoma. Neoplasia. 1999;1:340–348
  17. Issa JP, Vertino PM, Boehm CD, Newsham IF, Baylin SB. Switch from monoallelic to biallelic human IGF2 promoter methylation during aging and carcinogenesis. Proc. Natl. Acad. Sci. USA. 1996;93:11757–11762
  18. Morison IM, Eccles MR, Reeve AE. Imprinting of insulin-like growth factor 2 is modulated during hematopoiesis. Blood. 2000;96:3023–3028
  19. Taniguchi T, Sullivan MJ, Ogawa O, Reeve AE. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor. Proc. Natl. Acad. Sci. USA. 1995;92:2159–2163
  20. Pedersen SK, Christiansen J, Hansen TO, Larsen MR, Nielsen FC. Human insulin like growth factor-II leader 2 mediates internal initiation of translation. Biochem. J. 2002;363:37–44
  21. Von Horn H, Ekström C, Ellis E, Olivecrona H, Einarsson C, Tally M, et al. GH is a regulator of IGF2 promoter-specific transcription in human liver. J. Endocrinol. 2002;172:457–465
  22. Li X, Adam G, Cui H, Sandstedt B, Ohlsson R, Ekström TJ. Expression, promoter usage and parental imprinting status of insulin-like growth factor II (IGF2) in human hepatoblastoma: uncoupling of IGF2 and H19 imprinting. Oncogene. 1995;11:221–229
  23. Wang WH, Duan JX, Vu TH, Hoffman AR. Increased expression of the insulin like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity. J. Biol. Chem. 1996;271:27863–27870
  24. Eriksson T, Frisk T, Gray SG, von Schweinitz D, Pietsch T, Larsson C, et al. Methylation changes in the human IGF2 P3 promoter, parallel IGF2 expression in primary tumor, established cell line, and xenograft of a human hepatoblastoma. Exp. Cell Res. 2001;270:88–95

PII: S0304-3835(05)00659-2

doi: 10.1016/j.canlet.2005.07.003

Cancer Letters
Volume 238, Issue 2 , Pages 224-229 , 18 July 2006

Article Tools

* Image Usage & Resolution